$SER News

Last published 19h ago

19h agoSERSerina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 – Dosing initiated in Cohort 2 of the registrational study ; topline single-ascending-dose data expected in the first half of 2027 –
19h agoSERSerina Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2mo agoSERSerina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireHUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug
2mo agoSERSerina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2GlobeNewswire- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were
3mo agoSERSerina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireEnrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to
3mo agoSERSerina Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireHUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™
3mo agoSERSerina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseGlobeNewswire- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability
3mo agoSERSerina Therapeutics Appoints Farrell Simon to its Board of DirectorsGlobeNewswireHUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug
4mo agoSERSerina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseGlobeNewswireData Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites in the US and
4mo agoSERGannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 ProgramGlobeNewswireHUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage
6mo agoSERSerina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePhase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to
7mo agoSERSerina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitGlobeNewswire– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of
7mo agoSERSerina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanGlobeNewswireHUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug
7mo agoSERSerina Therapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswire- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or
7mo agoSERSerina Therapeutics to Present at the 38th Annual Roth ConferenceGlobeNewswireHUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
8mo agoSERSerina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's DiseaseGlobeNewswire- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient
8mo agoSERSerina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's DiseaseGlobeNewswire- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for first patient dosing
9mo agoSERRegistration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar EventGlobeNewswire"Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics' CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development
9mo agoSERSerina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's diseaseGlobeNewswire- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or
10mo agoSERSerina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' EquityGlobeNewswireHUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND")
11mo agoSERSerina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of ChemistryGlobeNewswireHUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND")
11mo agoSERSerina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 ProgramGlobeNewswire– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback
1y agoSERSerina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswireHUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND")
1y agoSERSerina Therapeutics Provides Regulatory Update on SER-252 ProgramGlobeNewswire- FDA requests additional information on a formulation component - HUNTSVILLE, AL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing
1y agoSERSerina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and InvestorsGlobeNewswireHUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's DiseaseGlobeNewswire$5 million tranche received under up to $20 million financing agreementIND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) --
1y agoSERSerina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's DiseaseGlobeNewswireTransaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson's under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic
1y agoSERSerina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireHUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA PathwayGlobeNewswire- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina
1y agoSERSerina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswireHUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease,
1y agoSERSerina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)GlobeNewswire- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington's chorea – an underserved indication with high need for
1y agoSERSerina Therapeutics to Present at the BTIG Virtual Biotechnology ConferenceGlobeNewswireHUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics Makes Grant to New Employee Under Inducement PlanGlobeNewswireHUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease,
1y agoSERSerina Therapeutics Announces Date for 2025 Annual Stockholders MeetingGlobeNewswireHUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as
1y agoSERSerina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025GlobeNewswireHow Parkinson's affects million – and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson's careSerina's drug candidate SER-252 is designed to deliver
1y agoSERUPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42GlobeNewswireHUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology
1y agoSERSerina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42GlobeNewswireHUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today
1y agoSERRegistration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"GlobeNewswireFeaturing Serina Therapeutics' CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise valuesRecognize
1y agoSERSerina Therapeutics Appoints Stephen Brannan, M.D. to Board of DirectorsGlobeNewswire- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a
1y agoSERSerina Therapeutics Makes Grants to New Employees Under Inducement PlanGlobeNewswireHUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease,
1y agoSERSerina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswireOn track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple
1y agoSERSerina Therapeutics to Present at JonesResearch Virtual CNS DayGlobeNewswireHUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics to Present at the 4th LNP Formulation & Process Development SummitGlobeNewswireHUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's DiseaseGlobeNewswireHUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics to Present at the Jones Healthcare and Technology Innovation ConferenceGlobeNewswireHUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics Reports Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswireHUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today
1y agoSERSerina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 MeetingGlobeNewswireHUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology,
1y agoSERSerina Therapeutics Appoints Dr. Jay Venkatesan to its Board of DirectorsGlobeNewswireHUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology,
1y agoSERSerina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease PatientsGlobeNewswireHUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its
1y agoSERSerina Therapeutics Announces Sale of UniverXome SubsidiaryGlobeNewswire- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology